Curis (CRIS) Net Income (2010 - 2026)
Curis' (CRIS) quarterly Net Income came in at -$11.7 million in Q1 2026, down 10.61% YoY from -$13.1 million in Q1 2025, and down 160.66% on a QoQ basis from $19.4 million in Q4 2025.
Curis (CRIS) Net Income (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Net Income data on file, last reported at -$11.7 million in Q1 2026.
- Quarterly Net Income fell 10.61% year-over-year to -$11.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.7 million (up 80.02% YoY) and the FY2025 annual result came in at -$217.2 million, up 14.78% from the prior year.
- Net Income slipped to -$11.7 million in Q1 2026, from $19.4 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $19.4 million in Q4 2025 to a low of -$16.5 million in Q1 2022.
- A 5-year average of -$10.0 million and a median of -$11.7 million in 2026 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income sank 62.8% — and 2025, when it soared 291.17%.
- Tracing CRIS's Net Income over 5 years: stood at -$10.4 million in 2022, then slipped by 9.57% to -$11.4 million in 2023, then grew by 11.0% to -$10.1 million in 2024, then soared by 291.17% to $19.4 million in 2025, then sank by 160.66% to -$11.7 million in 2026.
- The last three Net Income figures came in at -$11.7 million (Q1 2026), $19.4 million (Q4 2025), and -$7.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | -9.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.74 Mn |
| Dec 31, 2025 | 19.36 Mn |
| Sep 30, 2025 | -7.73 Mn |
| Jun 30, 2025 | -8.59 Mn |
| Mar 31, 2025 | -10.62 Mn |
| Dec 31, 2024 | -10.13 Mn |
| Sep 30, 2024 | -10.64 Mn |
| Jun 30, 2024 | -12.21 Mn |
| Mar 31, 2024 | -12.76 Mn |
| Dec 31, 2023 | -11.38 Mn |
| Sep 30, 2023 | -12.89 Mn |
| Jun 30, 2023 | -12.78 Mn |
| Mar 31, 2023 | -12.09 Mn |
| Dec 31, 2022 | -10.38 Mn |
| Sep 30, 2022 | -13.29 Mn |
| Jun 30, 2022 | -16.21 Mn |
| Mar 31, 2022 | -16.53 Mn |
| Dec 31, 2021 | -13.78 Mn |
| Sep 30, 2021 | -11.11 Mn |
| Jun 30, 2021 | -11.78 Mn |